相似文献
1
Viewing RCC with a DNA Methylation Lens ENHANCES Understanding of ICI Resistance.
Clin Cancer Res. 2023 Apr 3;29(7):1170-1172. doi: 10.1158/1078-0432.CCR-22-3574.
2
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Clin Cancer Res. 2023 Apr 3;29(7):1279-1291. doi: 10.1158/1078-0432.CCR-22-2133.
3
Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Cancer Cell. 2024 May 13;42(5):732-735. doi: 10.1016/j.ccell.2024.03.002. Epub 2024 Apr 4.
4
Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Pathol Res Pract. 2021 Sep;225:153557. doi: 10.1016/j.prp.2021.153557. Epub 2021 Jul 20.
5
Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Clin Cancer Res. 2021 Mar 15;27(6):1734-1743. doi: 10.1158/1078-0432.CCR-20-3788. Epub 2021 Jan 7.
6
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Eur Urol. 2023 Feb;83(2):163-172. doi: 10.1016/j.eururo.2022.05.029. Epub 2022 Jun 15.
7
Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Int J Mol Sci. 2021 Mar 11;22(6):2832. doi: 10.3390/ijms22062832.
8
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000319.
9
Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Eur J Cancer. 2020 Sep;136:195-203. doi: 10.1016/j.ejca.2020.06.008. Epub 2020 Jul 23.
10
Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Pathol Int. 2020 Oct;70(10):712-723. doi: 10.1111/pin.12984. Epub 2020 Jul 11.
引用本文的文献
1
DNA methylation expression patterns predict outcome of clear cell renal cell carcinoma.
Discov Oncol. 2025 May 26;16(1):934. doi: 10.1007/s12672-025-02764-0.
2
Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Cell Rep Med. 2023 Nov 21;4(11):101287. doi: 10.1016/j.xcrm.2023.101287. Epub 2023 Nov 14.
本文引用的文献
1
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Clin Cancer Res. 2023 Apr 3;29(7):1279-1291. doi: 10.1158/1078-0432.CCR-22-2133.
2
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4.
3
PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner.
Cancer Immunol Res. 2022 Mar 1;10(3):285-290. doi: 10.1158/2326-6066.CIR-21-0480.
4
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Cancer Cell. 2021 Nov 8;39(11):1497-1518.e11. doi: 10.1016/j.ccell.2021.10.001. Epub 2021 Oct 28.
5
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma.
Clin Cancer Res. 2021 Mar 1;27(5):1371-1380. doi: 10.1158/1078-0432.CCR-20-3084. Epub 2020 Nov 20.
6
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Cancer Cell. 2020 Dec 14;38(6):803-817.e4. doi: 10.1016/j.ccell.2020.10.011. Epub 2020 Nov 5.
7
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.
Cancer Res. 2019 Jul 1;79(13):3383-3394. doi: 10.1158/0008-5472.CAN-18-1010. Epub 2019 Apr 30.
8
Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.
J Clin Invest. 2018 Nov 1;128(11):4804-4820. doi: 10.1172/JCI121476. Epub 2018 Oct 2.
9
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma.
JCI Insight. 2018 Aug 23;3(16). doi: 10.1172/jci.insight.121522.
10
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.
Nat Med. 2018 Oct;24(10):1550-1558. doi: 10.1038/s41591-018-0136-1. Epub 2018 Aug 20.
Zotero 插件